On Thu, 20 Feb 1997 22:31:14 -0500 Ron Reiner <[log in to unmask]>
writes:
>Complimentary IBM DB2 Fast Start Conference!
>SIBIA Neurosciences Commences Phase I
>Clinical Trials in Parkinson's Disease With Its
>Proprietary Compound Targeting Nicotinic
>Acetylcholine Receptors
>
>Source: PR Newswire
>
>LA JOLLA, Calif., Feb. 18 /PRNewswire/ via Individual Inc. -- SIBIA
>Neurosciences, Inc. (Nasdaq NNM: SIBI) today announced that it has
>commenced under a U.S. IND a Phase I clinical trial in Parkinson's
>disease with SIB-1508Y, the Company's proprietary neuronal nicotinic
>acetylcholine receptor agonist.
>
>The trial will evaluate the safety and pharmacokinetics of SIB-1508Y....
Is there anyone on our wonderful list who can help me to understand
the relationship between SIB-1508Y, NADH, and mitochondrial Complex 1?
The neurochemistry is becoming a neurochem-mystery!!
Ivan S.
